Glaxo Consumer Has Time To Spread Wings Before Potential Solo Flight
This article was originally published in The Tan Sheet
GlaxoSmithKline will not consider spinning off of its consumer health business for two to three years, when it can evaluate its "full value," says CEO Andrew Witty. Sales of the OTC intranasal corticosteroid Flonase Allergy Relief led the firm's US consumer business sales in the latest quarter and throughout 2015.
You may also be interested in...
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.
Thorne promotes Effusio dissolvable nutrient discs as a leg-up on competitors with highly absorbable ingredients delivered in a dissolvable disc without using plastic bottles. Launching with Probiotic + and Sleep +, the line will add an immune-boost formula later in 2021.
California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.